Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Refractory/Relapsed AML
NCT01664897Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2013
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started May 2013; status: completed.
02
Drugs
erlotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01664897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01664897.